[Fondaparinux and lepirudin as therapeutic alternatives in a disseminated eczematous skin reaction to low-molecular-weight heparin].
Santiago Sánchez-Mateos
D I
DI
Eguren
C
C
de Argila
D
D
Sánchez-Pérez
J
J
D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects*; D017449:Dermatitis, Allergic Contact / Q000209:etiology*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects*; D006629:Hirudins; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006629:Hirudins; D011134:Polysaccharides; D011994:Recombinant Proteins; D000077425:Fondaparinux; C083544:lepirudin